Grifols, S.A.

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BARCELONA, Spain, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced that it has completed Cohort 1 of its Phase 1/2 study (NCT04722887) evaluating Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), a subcutaneous (SC) alpha1 antitrypsin (AAT) treatment being compared to Liquid Alpha1-Proteinase Inhibitor (Human) intravenous (IV).

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Researchers from the National Cancer Institute will conduct the Phase 1 trial , as established in a recently signed Cooperative Research and Development Agreement (CRADA)

GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023

Grifols, S.A. (NASDAQ:GRFS ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Nuria Pascual - IR and Sustainability Officer Thomas Glanzmann - Executive Chairman and CEO Victor Grifols Deu - COO Alfredo Arroyo - CFO Conference Call Participants Thomas Jones - Joh.

Grifols, S.A. (GRFS) Q3 2023 Earnings Call Transcript

Grifols shares soared in early trading on Thursday after the Spanish drugmaker upgraded its annual profit outlook following a strong quarter.

Grifols shares soar after 2023 profit outlook upgrade

ZARAGOZA, Spain, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Araclon Biotech, a Grifols Group company dedicated to the research and development of therapies and diagnostic methods applied to neurodegenerative diseases, today announced encouraging final results from its Phase 2 trial (NCT03461276) of ABvac40, an active vaccine against the Aβ40 peptide, for the treatment of patients with early-stage Alzheimer's disease (AD). Araclon gave a late-breaking presentation at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference.

Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer's Vaccine at CTAD

DALLAS--(BUSINESS WIRE)--Advanced Infusion Care (AIC), a division of AIS Healthcare, today announced an agreement to conduct a joint study with Grifols, a leading global provider of essential plasma-derived and transfusion medicines, to observe the effects of subcutaneous immunoglobulin (SCIG) products on individuals living with primary immune deficiencies (PID). AIC and Grifols' Satisfaction and Outcomes in Primary Immune Deficiency patients (SOPID) study will observe 60 patients across a thre.

AIS Healthcare's Advanced Infusion Care Announces Joint Study with Grifols to Continue Improving Patient Care

Modified agreement expands total grant value to $11.8M to advance development activities including manufacturing and investigational new drug (IND)-enabling studies Modified agreement expands total grant value to $11.8M to advance development activities including manufacturing and investigational new drug (IND)-enabling studies

GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins

Collaboration sets stage for GigaGen's first oncology asset to enter clinical development GIGA-564 is a differentiated anti-CTLA4 antibody with potential to enhance anti-tumor activity and mitigate immune-related toxicities associated with traditional CTLA-4 blockade GigaGen and NCI will present investigational new drug (IND)-enabling data and clinical trial strategy for GIGA-564 at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting SAN CARLOS, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) --   GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, announced today that it has signed an agreement with the National Cancer Institute (NCI), part of the National Institutes of Health, to advance development of the company's differentiated anti-CTLA-4 antibody drug candidate for cancer treatment, GIGA-564.

GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564

Stevanato Group SpA

Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two companies is the best option for those looking for undervalued stocks?

GRFS or STVN: Which Is the Better Value Stock Right Now?

Grifols (GRFS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Grifols (GRFS) Upgraded to Strong Buy: What Does It Mean for the Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Grifols (GRFS) Stock?

Grifols, S.A. (NASDAQ:GRFS ) Q2 2023 Earnings Conference Call July 27, 2023 8:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - our Executive Chairman and CEO Alfredo Arroyo - CFO Victor Grifols Deu - COO Conference Call Participants Peter Verdult - Citi James Gordon - JPMorgan Jaime Escribano - Banco Santander Thibault Boutherin - Morgan Stanley Tom Jones - Berenberg Guilherme Sampaio - CaixaBank Alvaro Lenze - Alantra Equities Joaquín García-Quirós - JB Capital Nuria Pascual Hello everyone, and welcome to the Grifols' Second Quarter 2023 Conference Call.

Grifols, S.A. (GRFS) Q2 2023 Earnings Call Transcript

BARCELONA, Spain, July 20, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced that its recently concluded phase 4 trial (NCT04566692) evaluating a biweekly dosing of XEMBIFY® has met its primary endpoint. It has demonstrated that patients with primary immunodeficiencies (PIDs) treated with this subcutaneous 20% immunoglobulin (SCIg) product every two weeks achieved non-inferiority in total Ig levels compared with those who received the medication weekly.

Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients

BARCELONA, Spain, July 18, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced it has completed enrollment in PRECIOSA (NCT03451292), its phase 3 clinical trial designed to determine the potential of long-term albumin treatment with Grifols Albutein® to increase survival time in patients with decompensated cirrhosis and ascites until a suitable transplant is available.

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols is a promising buy opportunity thanks to its potential to reduce its net debt/EBITDA ratio. The company's focus on deleveraging is showing results and is supported by higher savings and better margins. The plasma collection is also recovering. Better-than-anticipated results and a compelling valuation make Grifols a buy.

Grifols: A Promising Buy Opportunity

I've reviewed Grifols once before and gave you my overall thesis on what I believe to be a solid pharma/biotech company. Investing in Spanish stocks without a dividend and worrying fundamentals is always a "thing" but I'll provide here why I have a small position in the company.

Grifols: Upside After A Smashing Q1 2023 - I Say 'Buy'

BARCELONA, Spain, May 11, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma-derived medicines and innovative diagnostic solutions, today announced it has launched its AlphaID™ At Home Genetic Health Risk Service (AlphaID™ At Home), the first-ever free direct-to-consumer program in the U.S., to screen for the genetic risk of alpha1-antitrypsin deficiency (alpha-1).

Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD

Grifols, S.A. (NASDAQ:GRFS ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - Executive Chairman Victor Grifols Deu - Co-CEO Alfredo Arroyo - CFO Conference Call Participants Jo Walton - Credit Suisse James Gordon - JP Morgan Guilherme Sampaio - CaixaBank BPI Tom Jones - Berenberg Jaime Escribano - Banco Santander Charles Pitman - Barclays Vineet Agrawal - Citi Nuria Pascual Hello, everyone, and welcome to the Grifols First Quarter 2023 conference call.

Grifols, S.A. (GRFS) Q1 2023 Earnings Call Transcript

Grifols' first-quarter report came a day after it announced a new leadership team. The company upgraded half-year and full-year guidance.

Why Shares of Grifols Were Up Tuesday

BARCELONA, Spain , April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines that has been enhancing people's health and well-being for more than 110 years, today announces the filling of its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, with the United States Securities and Exchange Commission ("SEC").

Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023

Are Investors Undervaluing Grifols (GRFS) Right Now?

Grifols (GRFS) Upgraded to Strong Buy: Here's Why

CHICAGO , March 6, 2023 /PRNewswire/ -- Selagine, Inc., a spin-out company from the University of Illinois at Chicago (UIC), announced today that it has entered into a research, development and sublicense agreement with Grifols (Nasdaq: GRFS), a global leader in plasma-derived medicines, for the development and commercialization of immunoglobulin eye drops for dry eye disease. A novel biologic eyedrop that may change the treatment paradigm for dry eye disease An immunoglobulin eye drop is a biologic drug that contains naturally occurring functional antibodies generated from human plasma collected from thousands of healthy donors.

Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease

Is Grifols (GRFS) Stock Undervalued Right Now?

Grifols is a global, Spanish-based biotech company that is a favorite for many European investors, despite the fact that the company does not pay a dividend. It's one of the more well-known Spanish companies on the world stage, with headquarters in Barcelona, an 80+ year history under its belt, and employing over 20,000 people.

News for Grifols, S.A. Stock (GRFS)